MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ctr.70070

Медицинская библиотека · Clinical transplantation · 2025

Amyloidosis and Heart Transplantation in a New Era.

Lyle Melissa A, Farina Juan Maria M, Wiedmeier-Nutor Erin, Lindpere Vanda, Klanderman Molly, Nativi-Nicolau Jose N, Leoni Moreno Juan Carlos, Goswami Rohan M, Yip Daniel S, Patel Parag C, Sher Taimur, Rosenbaum Andrew N, AbouEzzeddine Omar F, Boilson Barry A, Kushwaha Sudhir S, Clavell Alfredo L, Steidley David E, Hardaway Brian W, Scott Robert L, LeMond Lisa M, Fonseca Rafael, Gertz Morie A, Dispenzieri Angela, Grogan Martha, Rosenthal Julie L

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.

OBJECTIVES

We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.

METHODS

This is a retrospective review of end-stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020. Wait time was compared in the new versus old OPTN allocation era starting December 18, 2018 by Wilcoxon rank sum test. All-cause mortality for those with and without CA was compared using Kaplan-Meier estimates with log rank analysis, censoring December 16, 2022.

RESULTS

Fifty-five patients with CA underwent HT between 2007 and 2020, 8 light chain amyloidosis (AL) (14.5%), 28 hereditary transthyretin (ATTRv) (50.9%), 17 wildtype transthyretin (ATTRwt) (30.9%), and 2 hereditary apolipoprotein A1 (AApoA1) amyloidosis patients (3.6%). No significant difference in overall survival post-transplant was seen in amyloid compared with non-amyloid (p = 0.816). Median time to HT was shorter in the new system, 45 days (IQR 24, 78) versus 174 days (IQR 76.5, 483.5), p = 0.006. There was a decline in MOT in hereditary amyloidosis over time with the concomitant rise in disease-targeted therapies.

CONCLUSIONS

HT survival in CA patients was similar to non-amyloid patients. The new allocation system benefits this cohort with shorter wait times. There is less MOT in hereditary amyloidosis with increased utilization of disease-targeted therapy.

Для цитирования: Lyle Melissa A, Farina Juan Maria M, Wiedmeier-Nutor Erin, Lindpere Vanda, Klanderman Molly, Nativi-Nicolau Jose N, Leoni Moreno Juan Carlos, Goswami Rohan M, Yip Daniel S, Patel Parag C, Sher Taimur, Rosenbaum Andrew N, AbouEzzeddine Omar F, Boilson Barry A, Kushwaha Sudhir S, Clavell Alfredo L, Steidley David E, Hardaway Brian W, Scott Robert L, LeMond Lisa M, Fonseca Rafael, Gertz Morie A, Dispenzieri Angela, Grogan Martha, Rosenthal Julie L. Amyloidosis and Heart Transplantation in a New Era.. Clinical transplantation. 2025. DOI: 10.1111/ctr.70070.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.